Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) in Patients With Hunter Syndrome

NCT07344376 is registered in ClinicalTrials.gov with GC Biopharma Corp as lead sponsor.

NCT NCT07344376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07344376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) in Patients With Hunter Syndrome
Lead sponsor
GC Biopharma Corp
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2018
Completion date
December 30, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gc1111, hunter syndrome, hunter syndrome (mps ii), hunterase, mps ii